Celsion logo

CLSN - Celsion Share Price

$0.54 0.0  2.7%

Last Trade - 9:00pm

Micro Cap
Market Cap £13.2m
Enterprise Value £1.60m
Revenue £375k
Position in Universe 5472nd / 6431
Unlock CLSN Revenue
Relative Strength (%)
1m -10.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -91.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.50 0.50 0.50 0.50 0.50 0.50 0.38 0.17
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CelsionCorporation revenues remained flat at $250K. Net lossincreased 26% to $10.4M. Revenues reflect marketconditions. Higher net loss reflects Other Non Rec. I/E -Non Business Activ. decrease from $3M (income) to $298K(expense), Investment income decrease of 58% to $109K(income). Basic Earnings per Share excluding ExtraordinaryItems increased from -$0.41 to -$0.37.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CLSN
Graphical History


CLSN Revenue Unlock CLSN Revenue

Net Income

CLSN Net Income Unlock CLSN Revenue

Normalised EPS

CLSN Normalised EPS Unlock CLSN Revenue

PE Ratio Range

CLSN PE Ratio Range Unlock CLSN Revenue

Dividend Yield Range

CLSN Dividend Yield Range Unlock CLSN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CLSN EPS Forecasts Unlock CLSN Revenue
Profile Summary

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 17, 2000
Public Since October 27, 1993
No. of Shareholders: 12,200
No. of Employees: 29
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 33,442,945
Free Float (0.0%)
Eligible for
CLSN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CLSN
Upcoming Events for CLSN
Frequently Asked Questions for Celsion
What is the Celsion share price?

As of 9:00pm, shares in Celsion are trading at $0.54, giving the company a market capitalisation of £13.2m. This share price information is delayed by 15 minutes.

How has the Celsion share price performed this year?

Shares in Celsion are currently trading at $0.54 and the price has moved by -60.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celsion price has moved by -64.92% over the past year.

What are the analyst and broker recommendations for Celsion?

Of the analysts with advisory recommendations for Celsion, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celsion is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Celsion next release its financial results?

Celsion is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Celsion dividend yield?

Celsion does not currently pay a dividend.

Does Celsion pay a dividend?

Celsion does not currently pay a dividend.

When does Celsion next pay dividends?

Celsion does not currently pay a dividend.

How do I buy Celsion shares?

To buy shares in Celsion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Celsion?

Shares in Celsion are currently trading at $0.54, giving the company a market capitalisation of £13.2m.

Where are Celsion shares listed? Where are Celsion shares listed?

Here are the trading details for Celsion:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CLSN
What kind of share is Celsion?

Based on an overall assessment of its quality, value and momentum, Celsion is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Celsion share price forecast 2020?

Shares in Celsion are currently priced at $0.54. At that level they are trading at 1.04% discount to the analyst consensus target price of 0.00.

Analysts covering Celsion currently have a consensus Earnings Per Share (EPS) forecast of -0.633 for the next financial year.

How can I tell whether the Celsion share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celsion. Over the past six months, the relative strength of its shares against the market has been -84.51%. At the current price of $0.54, shares in Celsion are trading at -62.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Celsion PE Ratio?

We were not able to find PE ratio data for Celsion.

Who are the key directors of Celsion?

Celsion's management team is headed by:

Michael Tardugno - DRC
Pok Yu Chow - IND
Nicholas Borys - SVP
Jeffrey Church - CFO
Robert Hooper - IND
Alberto Martinez - IND
Frederick Fritz - IND
Khursheed Anwer - EVP
Donald Braun - IND
Who are the major shareholders of Celsion?

Here are the top five shareholders of Celsion based on the size of their shareholding:

Lincoln Park Capital Investment Advisor
Percentage owned: 4.73% (1.58m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.02% (1.35m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.86% (955k shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 2.09% (700k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 2.06% (687k shares)
Similar to CLSN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.